C83.17
Mantle cell lymphoma, spleen
Clinical Classification Guidelines
Medical Intelligence & Overview
Mantle cell lymphoma of the spleen is a rare type of non-Hodgkin lymphoma that originates in the mantle zone of lymphoid follicles, primarily affecting the spleen. It is a subtype of B-cell lymphoma and tends to be more aggressive than some other lymphomas. This form of lymphoma can involve other parts of the lymphatic system and organs, making diagnosis and treatment complex. Recognizing the symptoms, causes, and available diagnostic methods is vital for appropriate management.
Causes & Symptoms
Clinical Causes: Genetic mutations involving the cyclin D1 gene (CCND1), which leads to abnormal cell growth. Age-related factors, as it is more common in older adults. Potential environmental exposures, although specific risks are not well established. Family history of lymphoma or other lymphoid malignancies, suggesting a possible genetic predisposition.
Key Symptoms: Enlarged spleen (splenomegaly), which may cause discomfort or fullness in the abdomen. Unintentional weight loss over a period of time. Persistent fever without an identifiable infection. Night sweats that interfere with daily activities. Fatigue and weakness due to anemia or general malaise. Painless swelling of lymph nodes, often not limited to the spleen. Frequent infections due to immune system impairment.
Diagnostic & Treatment
Diagnosis Path: Diagnosing mantle cell lymphoma of the spleen involves a combination of clinical assessment, imaging studies, and laboratory tests: - **Physical examination:** To check for enlarged lymph nodes or spleen. - **Imaging tests:** Such as ultrasound, computed tomography (CT), or positron emission tomography (PET) scans to visualize the extent of organ involvement. - **Biopsy:** Removal of tissue from the spleen or affected lymph nodes for microscopic examination. - **Histopathological analysis:** To identify characteristic features of mantle cell lymphoma. - **Immunophenotyping:** To detect specific markers on the lymphoma cells. - **Molecular testing:** Including fluorescence in situ hybridization (FISH) to identify genetic abnormalities like the t(11;14) translocation that is typical in mantle cell lymphoma.
Treatment Protocols: Treatment strategies for mantle cell lymphoma of the spleen depend on the stage of the disease and the patient’s overall health: - **Chemotherapy:** Often combined with immunotherapy agents such as rituximab. - **Targeted therapy:** Including drugs that specifically target lymphoma cells, such as BTK inhibitors. - **Radiation therapy:** May be used in localized cases or for palliation. - **Stem cell transplantation:** Considered for eligible patients to achieve long-term remission. - **Supportive care:** Managing symptoms, infections, and side effects of treatment. Early diagnosis and tailored treatment are crucial for improving outcomes, as mantle cell lymphoma can be aggressive and challenging to treat.
Clinical Advice & FAQs
Billing Guidance
Is C83.17 a billable ICD-10 code?
Yes, C83.17 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C83.17?
Clinical documentation must specify the nature of Mantle cell lymphoma, spleen and any associated comorbidities for accurate reporting.
Cite this Clinical Reference